[go: up one dir, main page]

MX2016000782A - Composiciones para modular la expresion de tau. - Google Patents

Composiciones para modular la expresion de tau.

Info

Publication number
MX2016000782A
MX2016000782A MX2016000782A MX2016000782A MX2016000782A MX 2016000782 A MX2016000782 A MX 2016000782A MX 2016000782 A MX2016000782 A MX 2016000782A MX 2016000782 A MX2016000782 A MX 2016000782A MX 2016000782 A MX2016000782 A MX 2016000782A
Authority
MX
Mexico
Prior art keywords
methods
compositions
tau
compounds
ameliorate
Prior art date
Application number
MX2016000782A
Other languages
English (en)
Other versions
MX379535B (es
Inventor
Eric E Swayze
Susan M Freier
Holly Kordasiewicz
Huynh-Hoa Bui
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of MX2016000782A publication Critical patent/MX2016000782A/es
Publication of MX379535B publication Critical patent/MX379535B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se describen en la presente compuestos antisentido y métodos para disminuir la expresión de proteína y ARNm de Tau. Dichos métodos, compuestos y composiciones son útiles para tratar, prevenir o mejorar las enfermedades, trastornos y afecciones relacionadas con Tau.
MX2016000782A 2013-07-19 2014-07-21 Composiciones para modular la expresión de tau. MX379535B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361856551P 2013-07-19 2013-07-19
US201361879621P 2013-09-18 2013-09-18
US201361885371P 2013-10-01 2013-10-01
US201462014486P 2014-06-19 2014-06-19
PCT/US2014/047486 WO2015010135A2 (en) 2013-07-19 2014-07-21 Compositions for modulating tau expression

Publications (2)

Publication Number Publication Date
MX2016000782A true MX2016000782A (es) 2016-06-28
MX379535B MX379535B (es) 2025-03-11

Family

ID=52346860

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000782A MX379535B (es) 2013-07-19 2014-07-21 Composiciones para modular la expresión de tau.
MX2021001207A MX2021001207A (es) 2013-07-19 2016-01-19 Composiciones para modular la expresion de tau.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001207A MX2021001207A (es) 2013-07-19 2016-01-19 Composiciones para modular la expresion de tau.

Country Status (25)

Country Link
US (4) US9683235B2 (es)
EP (2) EP3022217B1 (es)
JP (4) JP6684707B2 (es)
KR (6) KR102273926B1 (es)
CN (3) CN113667667A (es)
AU (2) AU2014290395B2 (es)
BR (1) BR112016000654B1 (es)
CA (2) CA2918600C (es)
CY (1) CY1124292T1 (es)
DK (1) DK3022217T3 (es)
ES (1) ES2871533T3 (es)
HR (1) HRP20211051T1 (es)
HU (1) HUE055144T2 (es)
IL (4) IL279572B2 (es)
LT (1) LT3022217T (es)
MX (2) MX379535B (es)
NZ (2) NZ755605A (es)
PL (1) PL3022217T3 (es)
PT (1) PT3022217T (es)
RS (1) RS62054B1 (es)
RU (1) RU2735551C2 (es)
SI (1) SI3022217T1 (es)
SM (1) SMT202100371T1 (es)
TW (4) TWI702046B (es)
WO (1) WO2015010135A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
JP6492003B2 (ja) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
EP2839006B1 (en) * 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
RU2015104762A (ru) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. Хиральный контроль
AU2014236156C1 (en) 2013-03-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
UY36550A (es) * 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
ES2820713T3 (es) * 2015-03-25 2021-04-22 Univ Degli Studi Di Trento Terapia mediada por ARN interferente para enfermedades neurodegenerativas
AU2016294347B2 (en) * 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US9840710B2 (en) 2015-11-18 2017-12-12 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
US10370667B2 (en) 2015-11-18 2019-08-06 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
KR102706686B1 (ko) 2016-05-06 2024-09-19 아이오니스 파마수티컬즈, 인코포레이티드 Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
JOP20190065A1 (ar) * 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
IL266862B2 (en) * 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
US11453881B2 (en) * 2018-03-13 2022-09-27 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
SG11202011397QA (en) * 2018-05-22 2020-12-30 Ionis Pharmaceuticals Inc Modulators of apol1 expression
AU2019287635A1 (en) * 2018-06-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
TWI833770B (zh) * 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
CR20210179A (es) 2018-07-03 2022-05-23 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
US20210230598A1 (en) * 2018-07-04 2021-07-29 National University Corporation Tokai National Higher Education And Research System Oligonucleotides for controlling tau splicing, and uses thereof
TWI856973B (zh) 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
US12318427B2 (en) 2018-10-02 2025-06-03 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CA3133247A1 (en) * 2019-03-15 2020-09-24 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing kcnt1 expression
AU2021230473A1 (en) * 2020-03-01 2022-09-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP4121537A4 (en) * 2020-03-18 2024-07-31 University Of Massachusetts OLIGONUCLEOTIDES FOR MAPT MODULATION
JP2023521604A (ja) * 2020-03-30 2023-05-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 微小管関連タンパク質タウ（ＭＡＰＴ）ｉＲＮＡ剤組成物およびその使用方法
IL297435A (en) * 2020-05-01 2022-12-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating atxn1
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US20220195437A1 (en) * 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
UY39713A (es) 2021-04-01 2022-10-31 Biogen Ma Inc Administracion de acido nucleico al sistema nervioso central
EP4405484A2 (en) 2021-09-24 2024-07-31 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
WO2023175091A2 (en) * 2022-03-16 2023-09-21 Janssen Pharmaceutica Nv MAPT siRNA AND USES THEREOF
US20250304958A1 (en) * 2022-05-13 2025-10-02 Julius-Maximilians-Universität Würzburg Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease
AR131530A1 (es) * 2022-12-29 2025-03-26 Voyager Therapeutics Inc Composiciones y métodos para la regulación de mapt
TW202434730A (zh) * 2023-02-10 2024-09-01 日商大塚製藥股份有限公司 Tau剪接轉換寡核苷酸及用於治療或預防tau相關疾病之醫藥組合物
WO2024220930A2 (en) * 2023-04-20 2024-10-24 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
WO2025026390A1 (zh) * 2023-08-01 2025-02-06 上海拓界生物医药科技有限公司 靶向MAPT的dsRNA及其医药用途
TW202515584A (zh) * 2023-10-11 2025-04-16 大陸商上海舶望製藥有限公司 用於抑制微管相關蛋白ｔａｕ（ｍａｐｔ）表達的組合物和方法
US20250283084A1 (en) 2024-03-08 2025-09-11 Eli Lilly And Company Mapt antisense oligonucleotide

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1027347A (en) 1910-11-23 1912-05-21 Columbus K Lassiter Multiple-spindle drill.
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
ATE154246T1 (de) 1990-07-27 1997-06-15 Isis Pharmaceuticals Inc Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
CA2122365C (en) 1991-11-26 2010-05-11 Brian Froehler Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US20040054156A1 (en) 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
JPH06329551A (ja) * 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
GB9323483D0 (en) 1993-11-13 1994-01-05 Cerestar Holding Bv Edible composition and a process for its preparation
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6617162B2 (en) * 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US5942275A (en) 1997-10-27 1999-08-24 The Procter & Gamble Company Flavored nut spreads having milk chocolate flavor and creamy soft texture
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
TR200102328T2 (tr) 1999-02-12 2002-01-21 Sankyo Company Limited Yeni nükleosid ve oligonükleotid analogları
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
EP1171586B1 (en) 1999-04-21 2013-06-12 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
EP1097941A1 (en) 1999-11-05 2001-05-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies
BR0016154A (pt) * 1999-12-08 2003-02-25 Xcyte Therapies Inc Depsipeptida e seus congêneres papa uso como imunossupressores
AU4036600A (en) 2000-03-28 2001-10-08 Isis Pharmaceuticals Inc Alteration of cellular behavior by antisense modulation of mrna processing
WO2001077384A2 (de) 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
EA006654B1 (ru) 2001-01-16 2006-02-24 Женсет С. А. Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003054143A2 (en) 2001-10-25 2003-07-03 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
EP1472335A4 (en) 2001-11-08 2005-12-28 Univ Johns Hopkins METHODS AND SYSTEMS FOR SEQUENCING NUCLEIC ACIDS
US20070203333A1 (en) 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050153336A1 (en) * 2002-03-29 2005-07-14 Bennett C. F. Compositions and their uses directed to nucleic acid binding proteins
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20040110149A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of BUB1-beta expression
AU2003268032A1 (en) 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
AU2003255435A1 (en) 2002-08-14 2004-03-03 Universitat Zurich A cellular assay system for neurofibrillary tangle formation
WO2004035765A2 (en) 2002-10-18 2004-04-29 Nucleonics, Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
EP2957568B1 (en) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US20080318210A1 (en) 2003-08-27 2008-12-25 Rosetta Genomics Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
JP2004187609A (ja) * 2002-12-12 2004-07-08 Sankyo Co Ltd 最適アンチセンス配列の決定法
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
KR20060002743A (ko) 2002-12-31 2006-01-09 악사론 바이오사이언스 아게 조혈성장인자에 의한 신경학적 질환의 치료방법
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050108783A1 (en) 2003-09-23 2005-05-19 Chihiro Koike Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CN100410383C (zh) 2004-05-11 2008-08-13 中国农业科学院生物技术研究所 一种昆虫杆状病毒生物反应器的制备方法
US8367360B2 (en) 2004-06-21 2013-02-05 Proteome Sciences Plc Method of screening for inhibitors of tau protein phosphororylation by tyrosine kinase c-Abl
AU2005299296A1 (en) 2004-10-27 2006-05-04 Vanderbilt University Mammalian genes involved in infection
US20080003570A1 (en) 2004-12-22 2008-01-03 The General Hospital Corporation Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein
JP5148476B2 (ja) 2005-03-21 2013-02-20 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 流体自動供給手段を有するパーソナルケア機器
US20060216722A1 (en) 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
US20090176725A1 (en) 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
AU2006284855B2 (en) 2005-08-29 2011-10-13 Regulus Therapeutics Inc. Methods for use in modulating miR-122a
US7858747B2 (en) 2005-08-30 2010-12-28 Novo Nordisk A/S Expression of proteins in E.coli
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
EP1986699A4 (en) 2006-01-26 2010-12-15 Univ Massachusetts RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE
DK2314594T3 (da) 2006-01-27 2014-10-27 Isis Pharmaceuticals Inc 6-modificerede bicykliske nukleinsyreanaloger
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
CA2651042A1 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP2010505897A (ja) 2006-10-11 2010-02-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ インフルエンザターゲット
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
CA2682497C (en) 2007-04-05 2017-08-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
KR101531934B1 (ko) 2007-05-01 2015-06-29 산타리스 팔마 에이/에스 Ｔｎｆ 슈퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질병 치료에 있어서의 그의 용도
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
US20100261175A1 (en) 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
KR101654007B1 (ko) 2007-08-15 2016-09-05 아이오니스 파마수티컬즈, 인코포레이티드 테트라하이드로피란 핵산 유사체
US20090076725A1 (en) 2007-09-14 2009-03-19 Kulvir Singh Bhogal Conveyance mode aware navigation device
EP2227545A2 (en) 2007-11-09 2010-09-15 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009124341A1 (en) 2008-04-07 2009-10-15 The University Of Queensland Rna molecules and uses thereof
BRPI0801674B1 (pt) 2008-06-04 2015-08-18 Luiz Carmine Giunti De Oliveira Formulação de creme de alfarroba com avelã sem adição de açúcar, sem lactose e sem glúten
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010048497A1 (en) 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
BRPI0901526A2 (pt) 2009-05-19 2011-01-18 Laerte Casoni José formulação de pasta de avelã sem adição de sacarose, enriquecida com fibras
CN115227710A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
JP2014501097A (ja) 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
JP2014501489A (ja) 2009-07-06 2014-01-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド 細胞ベースのバイオプロセシング
US20110041191A1 (en) 2009-07-09 2011-02-17 Bettina Platt Animal model, and products and methods useful for the production thereof
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
CN102482670B (zh) 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
CN104894129B (zh) * 2009-09-11 2020-07-10 Ionis制药公司 亨廷顿表达的调节
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
CN102753186B (zh) * 2010-01-08 2016-09-14 Isis制药公司 血管生成素样3表达的调节
EP3561060A1 (en) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
GB2471149B (en) 2010-03-04 2011-06-08 Eger Olive Oil Products Industry Ltd Dr Olive oil based flavoured spreads
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US9193969B2 (en) 2010-04-19 2015-11-24 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
WO2012005898A2 (en) 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
WO2012145582A2 (en) 2011-04-22 2012-10-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US8906441B2 (en) 2011-09-22 2014-12-09 Hormel Foods Corporation Peanut spread
WO2013066721A2 (en) 2011-11-04 2013-05-10 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of met by double-stranded rna
WO2013078441A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BE1020640A3 (nl) 2011-12-03 2014-02-04 Cavalier Nv Een met vezels verrijkte vulsamenstelling voor een chocoladeproduct.
JP6492003B2 (ja) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
CA2873801A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating apoa1 and abca1 expression
RU2015104762A (ru) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. Хиральный контроль
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
GB201301233D0 (en) 2013-01-24 2013-03-06 Queen Mary & Westfield College Method
ITGE20130015A1 (it) 2013-02-01 2014-08-02 Microtem Di Mattia Chiodetti E Savi No Larocca Snc Dispositivo di tenuta meccanica, in particolare per alberi di trasmissione in navi, natanti o simili
AU2014236156C1 (en) 2013-03-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
SG10201906382QA (en) 2013-05-01 2019-08-27 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv and ttr expression
DK3007564T3 (da) 2013-06-10 2020-03-09 Cargill Inc Struktureret fedtsystem
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
DE102013108693B3 (de) 2013-08-12 2014-12-24 Mars Inc. Schale
CA2926341A1 (en) 2013-10-14 2015-04-23 Ionis Pharmaceuticals, Inc. Methods for modulating expression of c9orf72 antisense transcript
EP3068233B1 (en) 2013-11-15 2018-12-26 AAK AB (publ) Cocoa butter stabilizing vegetable fat composition
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
US20170211064A1 (en) 2014-07-29 2017-07-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
UY36550A (es) 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
ES2820713T3 (es) 2015-03-25 2021-04-22 Univ Degli Studi Di Trento Terapia mediada por ARN interferente para enfermedades neurodegenerativas
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
KR102722052B1 (ko) 2015-09-29 2024-10-28 번지 로더스 크로클란 비.브이. 온도 내성 초콜릿 스프레드 또는 충전재 및 제조 방법
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
AR109750A1 (es) 2016-09-29 2019-01-23 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de tau
US11453881B2 (en) 2018-03-13 2022-09-27 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
CR20210179A (es) 2018-07-03 2022-05-23 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
JP2022531876A (ja) 2019-05-08 2022-07-12 バイオジェン・エムエイ・インコーポレイテッド オリゴヌクレオチドの収束液相合成
US20250183291A1 (en) 2022-03-18 2025-06-05 Panasonic Energy Co., Ltd. Non-aqueous electrolyte secondary battery

Also Published As

Publication number Publication date
US20230323351A1 (en) 2023-10-12
JP7354342B2 (ja) 2023-10-02
TW202246503A (zh) 2022-12-01
PT3022217T (pt) 2021-05-28
RU2735551C2 (ru) 2020-11-03
MX2021001207A (es) 2021-04-12
US20210071176A1 (en) 2021-03-11
WO2015010135A2 (en) 2015-01-22
TWI772856B (zh) 2022-08-01
BR112016000654A2 (pt) 2017-12-12
TW201936200A (zh) 2019-09-16
IL260378B (en) 2021-01-31
KR20160034340A (ko) 2016-03-29
TW201503892A (zh) 2015-02-01
IL243609B (en) 2018-08-30
EP3910060A1 (en) 2021-11-17
CN108064227B (zh) 2021-07-06
JP2016528891A (ja) 2016-09-23
KR20250091306A (ko) 2025-06-20
CA3149282A1 (en) 2015-01-22
KR20240093742A (ko) 2024-06-24
SMT202100371T1 (it) 2021-07-12
JP2023164642A (ja) 2023-11-10
US11591595B2 (en) 2023-02-28
CA2918600C (en) 2022-05-03
AU2020250262B2 (en) 2023-01-12
NZ755605A (en) 2022-01-28
AU2014290395A1 (en) 2016-02-04
CA2918600A1 (en) 2015-01-22
KR20230062658A (ko) 2023-05-09
RS62054B1 (sr) 2021-07-30
KR102526525B1 (ko) 2023-04-28
KR20220108196A (ko) 2022-08-02
US9683235B2 (en) 2017-06-20
TWI702046B (zh) 2020-08-21
KR102424991B1 (ko) 2022-07-25
US20180094261A1 (en) 2018-04-05
ES2871533T3 (es) 2021-10-29
EP3022217B1 (en) 2021-04-07
WO2015010135A3 (en) 2015-04-02
CA3149282C (en) 2025-07-08
RU2016104824A (ru) 2017-08-24
CN113667667A (zh) 2021-11-19
HRP20211051T1 (hr) 2021-10-01
CN108064227A (zh) 2018-05-22
LT3022217T (lt) 2021-07-12
IL302146A (en) 2023-06-01
JP6684707B2 (ja) 2020-04-22
IL279572B1 (en) 2023-06-01
NZ715828A (en) 2022-07-01
PL3022217T3 (pl) 2021-10-18
HK1223626A1 (en) 2017-08-04
TW202043475A (zh) 2020-12-01
AU2020250262A1 (en) 2020-11-05
US12091662B2 (en) 2024-09-17
US10793856B2 (en) 2020-10-06
KR20210084698A (ko) 2021-07-07
SI3022217T1 (sl) 2021-08-31
BR112016000654B1 (pt) 2022-08-09
JP2020141670A (ja) 2020-09-10
HUE055144T2 (hu) 2021-11-29
JP2022103192A (ja) 2022-07-07
DK3022217T3 (da) 2021-06-28
TWI657819B (zh) 2019-05-01
EP3022217A4 (en) 2017-08-09
AU2014290395B2 (en) 2020-07-30
CY1124292T1 (el) 2022-07-22
MX379535B (es) 2025-03-11
IL279572B2 (en) 2023-10-01
US20160145617A1 (en) 2016-05-26
KR102273926B1 (ko) 2021-07-09
EP3022217A2 (en) 2016-05-25
CN120796262A (zh) 2025-10-17
IL279572A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021001207A (es) Composiciones para modular la expresion de tau.
WO2015017159A3 (en) Performing neighbour cell measurements based on historical data
PL3537562T3 (pl) Bezprzewodowy układ zarządzania akumulatorem
JO3553B1 (ar) تعديل المناعة ضد الورم
EP3248433C0 (en) POWER-SAVING CHANNEL ACCESS FOR WIRELESS DEVICES IN DENSE WIRELESS NETWORKS
UY33925A (es) Inhibidores tricíclicos de quinasas
HRP20181302T1 (hr) Terapija za obnavljanje mikrobiota (mrt), pripravci i postupci proizvodnje
WO2014160166A3 (en) Variable angle screws, plates and systems
EP3064003A4 (en) User equipment and mobility management entity and methods for periodic update in cellular networks
DK3066781T3 (da) Radiokommunikationssystem og -fremgangsmåde baseret på tidsdrejede bølger
BR112013032032A2 (pt) método de comunicação de área local sem fio e terminal de apoio do mesmo
EP3053379A4 (en) Cloud-authenticated site resource management devices, apparatuses, methods and systems
EP2728956A4 (en) RESOURCE PLANNING METHOD, WIRELESS ACCESS EQUIPMENT, AND COMMUNICATION SYSTEM
DK2944104T3 (da) Systemer og fremgangsmåder til trådløs parring og kommunikation til elektrostimulation
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
EP3079390A4 (en) Security key context distribution method, mobile management entity, and base station
MX2016002587A (es) Modulacion de la expresion de precalicreina (pkk).
IL229369A (en) Low-bandwidth system and methods for wireless data monitoring for moving devices
IL244182A0 (en) Preparations, methods and systems for the treatment of skin disorders
ZA201800772B (en) Distribution of system access information in wireless communication system
GB2535381B (en) Field plates on two opposed surfaces of double-based bidirectional bipolar transistor: devices, methods, and systems
EP2981141A4 (en) BASIC STATION, PROCESSOR AND COMMUNICATION CONTROL PROCEDURE
EP3051422A4 (en) DISTRIBUTION MANAGEMENT DEVICE, END UNIT AND DISTRIBUTION MANAGEMENT PROCESS
EP3689028A4 (en) MOBILITY MANAGEMENT IN WIRELESS NETWORKS
BR112015018006A2 (pt) curativo de feridas, método de fabricação de um curativo de feridas, novo curativo de feridas e novo método de fabricação de um curativo de feridas